• About
• Links
• Contact
• Sitemap
• 

Drug Delivery Technologies - Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies

The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products. Drug delivery companies not only stand to benefit from patent expiry by providing their reformulation services to pharmaceutical companies, but also by producing their own versions of branded products with improved delivery mechanisms. Thus, post-patent expiry sales can be switched from the ethical manufacturer to the drug delivery sector.

Drug Delivery Technologies: Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies is an up-to-date guide that assesses the current state of the drug delivery industry and its application to both the pharmaceutical and biotech industries. While the sector is still dominated by oral technologies, drug delivery systems have expanded to include more novel devices such as needleless injectables, PEGylation platforms and microelectromechanical devices. These technological advances extend the duration of a drug’s action, increase delivery to target sites, reduce delivery to unwanted sites, and maximize drug absorption.

The expanding market for biotechnology and gene-based products, which by their very nature are difficult to administer, represents an emerging opportunity for drug delivery technologies. These technologies are first expected to come to market as reformulations of existing macromolecular therapies, such as insulin. This report analyzes the markets for oral, inhalable, injectable, transmucosal, transdermal and niche drug delivery technologies as they apply to both biotech and traditional pharmacological compounds.

Key Features of This Report

• A thorough overview of both marketed and emerging drug delivery technologies set to impact the global pharmaceutical market
• Analysis of the opportunities and threats to the global drug delivery industry
• Profiles of drug delivery companies along with key financial figures and technology/product portfolios
• Market analysis and outlook for the leading drug delivery technologies, including oral, injectable, inhalable, transdermal, transmucosal and niche technologies
• Profiles of key emerging drug delivery technologies and profiles of leading companies, by type of technology
• An overview of the global drug delivery market, with sales for key drug delivery categories and key products within each one of the them
• Identification of key areas associated with the successful development of new drug delivery systems
• Critical assessment of market trends, forecasts and problems in the global drug delivery market
• Explanations of key technologies and mechanism of action of new drug delivery technologies and products utilizing them
• Thorough descriptions of important areas of research and development in the drug delivery market

What questions does this report answer?

• What are the key trends in the field of drug delivery as a whole?
• What are the major issues involved in the research and development of more effective drug delivery systems?
• What types of drug delivery technologies are currently in research and development in each of the main drug delivery categories?
• What is the value of new drug delivery technologies in terms of a product’s lifecycle management?
• Which new drug delivery systems are likely to provide the best commercial opportunities for their manufacturers?

Highlights of this report

• Discussion and analysis of the problems associated with the use of traditional drug delivery technologies: lack of patient compliance, considerable adverse effects, inferior clinical efficacy due to the lack of targeted delivery
• Identification of the hallenges to the development of better, more efficacious drug delivery technologies, with fewer side effects
• Focused analysis of the global market for major drug delivery technologies: oral, inhalable, injectable, transdermal, transmucosal and topical, as well as niche technologies, such as gene delivery
• Identification of the major products in research and development utilizing new technologies
• Highlights of the drug delivery systems that are most likely to impact the global market

Reasons to purchase

• Provides a comprehensive description of the current state of affairs in the global drug delivery field
• Provides a comprehensive description of the main drug delivery technologies and key products within each of the categories
• Asesses key products and technologies in clinical development
• Provides a guide to optimizing drug reformulation processes
• Provides a guide to business models of drug delivery companies
• Identifies key issues facing drug delivery and pharmaceutical companies in the development of new drug delivery systems

---

Table of Contents

• Table of Contents
•  
  • 1INTRODUCING THE FIELD OF DRUG DELIVERY15
    • 1.1THE VALUE OF DRUG DELIVERY SYSTEMS15
    • 1.2DRUG DELIVERY AND PRODUCT DIFFERENTIATION16
    • 1.3DRUG DELIVERY AND PATENT EXTENSION17
    • 1.4THE OPTIMAL TIME FOR REFORMULATION19
    • 1.5OPTIMIZING R&D RETURNS THROUGH DRUG DELIVERY20
    • 1.6OPPORTUNITIES AND THREATS TO THE DRUG DELIVERY SECTOR20
      • 1.6.1Opportunities for Growth in the Drug Delivery Sector21
      • 1.6.2Threats to Additional Growth in the Drug Delivery Sector24
    • 1.7BUSINESS MODELS OF DRUG DELIVERY COMPANIES26
  • 2AN OVERVIEW OF DRUG DELIVERY TECHNOLOGIES28
    • 2.1ORAL DRUG DELIVERY28
      • 2.1.1Controlled Release29
      • 2.1.2Sustained Release31
      • 2.1.3Chronomodulation31
      • 2.1.4Rapid Dissolving and Taste-masking Tablets31
      • 2.1.5Macromolecular Drug Delivery33
      • 2.1.6Microemulsion33
      • 2.1.7Pulsatile Drug Delivery34
    • 2.2INHALABLE DRUG DELIVERY35
      • 2.2.1Nebulizers36
      • 2.2.2Metered Dose Inhalers (MDIs)36
      • 2.2.3Dry Powder Inhalers (DPIs)37
      • 2.2.4Limitations of Pulmonary Delivery Systems for Systemic Delivery38
      • 2.2.5Aqueous Systems39
      • 2.2.6Crystallization Technology39
      • 2.2.7Electrohydrodynamic (EHD) Aerosol Delivery40
      • 2.2.8Liposomal Systems40
    • 2.3INJECTABLE DRUG DELIVERY41
      • 2.3.1Sustained Release Injectable Systems42
      • 2.3.2Liposomal Systems43
      • 2.3.3Needleless Systems43
      • 2.3.4New Injectable Technologies44
    • 2.4TRANSMUCOSAL DRUG DELIVERY44
      • 2.4.1Buccal Delivery45
      • 2.4.2Nasal47
      • 2.4.3Rectal48
      • 2.4.4Vaginal48
    • 2.5TRANSDERMAL DRUG DELIVERY49
      • 2.5.1Passive Formulations51
      • 2.5.2Active Formulations52
    • 2.6NICHE TECHNOLOGIES55
      • 2.6.1Topical Systems56
      • 2.6.2Gene Delivery58
      • 2.6.3Implantable Systems60
      • 2.6.4Drug Delivery Microchips63
      • 2.6.5Nanotechnology66
  • 3OVERVIEW OF GLOBAL DRUG DELIVERY MARKET70
    • 3.1IMPORTANCE OF DRUG DELIVERY70
    • 3.2GLOBAL DRUG DELIVERY MARKET BY GEOGRAPHIC AREA71
    • 3.3GLOBAL DRUG DELIVERY MARKET BY SEGMENT72
    • 3.4GLOBAL DRUG DELIVERY MARKET FORECASTS74
  • 4DRUG DELIVERY MARKET ANALYSIS77
    • 4.1KEY MARKET SEGMENTS77
      • 4.1.1Oral Drug Delivery77
        • 4.1.1.1Sales of Products Utilizing Oral Drug Delivery Technology77
        • 4.1.1.2Key Therapeutic Areas for Oral Drug Delivery84
        • 4.1.1.3Key Oral Drug Delivery Products Impacting Global Market86
        • 4.1.1.4The Outlook for Oral Drug Delivery Technology92
        • 4.1.1.5Drivers and Restraints93
      • 4.1.2Inhalable Drug Delivery93
        • 4.1.2.1Sales of Products Utilizing Inhalable Drug Delivery Technology93
        • 4.1.2.2Key Therapeutic Areas for Inhalable Drug Delivery96
        • 4.1.2.3Key Inhalable Drug Delivery Products Impacting Global Market97
        • 4.1.2.4The Outlook for Inhalable Drug Delivery Technology104
        • 4.1.2.5Drivers and Restraints105
      • 4.1.3Injectable Drug Delivery106
        • 4.1.3.1Sales of Products Utilizing Injectable Drug Delivery Technology106
        • 4.1.3.2Key Therapeutic Areas for Injectable Drug Delivery110
        • 4.1.3.3Key Injectable Drug Delivery Products Impacting Global Market113
        • 4.1.3.4The Outlook for Injectable Drug Delivery Technology116
        • 4.1.3.5Drivers and Restraints117
      • 4.1.4Transmucosal Drug Delivery117
        • 4.1.4.1Sales of Products Utilizing Transmucosal Drug Delivery Technology117
        • 4.1.4.2Key Therapeutic Areas for Transmucosal Delivery120
        • 4.1.4.3Key Transmucosal Drug Delivery Products Impacting Global Market121
        • 4.1.4.4The Outlook for Transmucosal Drug Delivery Technology125
        • 4.1.4.5Drivers and Restraints126
      • 4.1.5Transdermal Drug Delivery127
        • 4.1.5.1Sales of Products Utilizing Transdermal Drug Delivery Technology127
        • 4.1.5.2Key Therapeutic Areas for Transdermal Drug Delivery131
        • 4.1.5.3Key Transdermal Drug Delivery Products Impacting Global Market133
        • 4.1.5.4The Outlook for Transdermal Drug Delivery Technology137
        • 4.1.5.5Drivers and Restraints137
      • 4.1.6Niche Drug Delivery Technologies138
        • 4.1.6.1Sales of Products Utilizing Niche Drug Delivery Technologies138
        • 4.1.6.2Key Niche Drug Delivery Technology Product Impacting Global Market141
        • 4.1.6.3The Outlook for Niche Drug Delivery Technologies142
        • 4.1.6.4Drivers and Restraints143
  • 5EMERGING DRUG DELIVERY TECHNOLOGIES: ORAL DRUG DELIVERY 144
    • 5.1KEY PRODUCT PROFILES151
    • 5.2KEY COMPANY INVOLVEMENT IN THE FIELD OF ORAL DRUG DELIVERY156
      • 5.2.1ALZA156
      • 5.2.2Biovail157
      • 5.2.3Cardinal Health161
      • 5.2.4Depomed163
      • 5.2.5Emisphere163
      • 5.2.6Ethypharm164
      • 5.2.7Penwest166
  • 6EMERGING DRUG DELIVERY TECHNOLOGIES: INHALABLE DRUG DELIVERY 167
    • 6.1KEY PRODUCT PROFILES168
    • 6.2KEY COMPANY INVOLVEMENT IN THE FIELD OF INHALABLE DRUG DELIVERY171
      • 6.2.13M171
      • 6.2.2Alkermes172
      • 6.2.3Aradigm172
      • 6.2.4Nektar173
      • 6.2.5SkyePharma175
  • 7EMERGING DRUG DELIVERY TECHNOLOGIES: INJECTABLE DRUG DELIVERY176
    • 7.1KEY PRODUCT PROFILES179
    • 7.2KEY COMPANY INVOLVEMENT IN THE FIELD OF INJECTABLE DRUG DELIVERY182
      • 7.2.1Alkermes182
      • 7.2.2ALZA182
      • 7.2.3Enzon183
      • 7.2.4Ethypharm184
      • 7.2.5Macromed185
      • 7.2.6Nektar185
      • 7.2.7QLT186
  • 8EMERGING DRUG DELIVERY TECHNOLOGIES: TRANSMUCOSAL DRUG DELIVERY188
    • 8.1KEY PRODUCT PROFILES190
    • 8.2KEY COMPANY INVOLVEMENT IN THE FIELD OF TRANSMUCOSAL DRUG DELIVERY193
      • 8.2.1Generex193
      • 8.2.2Nastech193
      • 8.2.3Pherin194
  • 9EMERGING DRUG DELIVERY TECHNOLOGIES: TRANSDERMAL DRUG DELIVERY197
    • 9.1KEY PRODUCT PROFILES199
    • 9.2KEY COMPANY INVOLVEMENT IN THE FIELD OF TRANSDERMAL DRUG DELIVERY202
      • 9.2.13M202
      • 9.2.2Altea Therapeutics203
      • 9.2.3ALZA204
      • 9.2.4Aradigm206
      • 9.2.5Noven207
  • 10EMERGING DRUG DELIVERY TECHNOLOGIES: NICHE DRUG DELIVERY TECHNOLOGIES209
    • 10.1KEY PRODUCT PROFILES212
    • 10.2KEY COMPANY INVOLVEMENT IN NICHE DRUG DELIVERY TECHNOLOGIES216
      • 10.2.1ALZA216
      • 10.2.2Connetics (now Stiefel Laboratories)216
      • 10.2.3Inovio217
      • 10.2.4MacroChem218
      • 10.2.5NexMed218
      • 10.2.6pSivida219
      • 10.2.7QLT220
      • 10.2.8SkyePharma221
  • 11KEY DRUG DELIVERY COMPANY PROFILES224
    • 11.13M PHARMACEUTICALS224
    • 11.2ALKERMES226
    • 11.3ALTEA THERAPEUTICS227
    • 11.4ALZA (JOHNSON & JOHNSON)229
    • 11.5ARADIGM231
    • 11.6BIOJECT232
    • 11.7BIOVAIL234
    • 11.8CARDINAL HEALTH236
    • 11.9CIMA LABS (CEPHALON)237
    • 11.10CONNETICS (STIEFEL LABORATORIES INC.)239
    • 11.11CYDEX PHARMACEUTICALS241
    • 11.12DELSITE BIOTECHNOLOGIES (CARRINGTON LABORATORIES)242
    • 11.13DEPOMED243
    • 11.14DOR BIOPHARMA245
    • 11.15DURECT247
    • 11.16EMISPHERE249
    • 11.17ENZON251
    • 11.18ETHYPHARM253
    • 11.19EURAND255
    • 11.20GENEREX256
    • 11.21INOVIO (FORMERLY GENETRONICS)258
    • 11.22IVAX (PART OF TEVA)261
    • 11.23MACROCHEM262
    • 11.24MACROMED (NOW PROTHERICS)263
    • 11.25NASTECH (NOW MDRNA)265
    • 11.26NEKTAR266
    • 11.27NEXMED269
    • 11.28NOVEN270
    • 11.29PSIVIDA272
    • 11.30PENWEST274
    • 11.31PHERIN PHARMACEUTICALS276
    • 11.32QLT277
    • 11.33SKYEPHARMA279
    • 11.34WATSON PHARMACEUTICALS281
    • 11.35ZOGENIX283
• Tables
• TABLE 2.1 DRUGS SUITABLE OR UNSUITABLE FOR CONTROLLED RELEASE30
• TABLE 2.2 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DELIVERY50
• TABLE 3.1 GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY KEY SEGMENTS, 200772
• TABLE 3.2 FORECAST GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY SEGMENT, US$ BILLION75
• TABLE 4.1 KEY ORAL DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN)78
• TABLE 4.2 LEADING ORAL DRUG DELIVERY COMPANIES 2007, KEY PRODUCTS AND SALES 2007 ($MN)83
• TABLE 4.3 KEY INHALABLE DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN)94
• TABLE 4.4 KEY INJECTABLE DRUG DELIVERY PRODUCTS, 2004-2007** ($ MN)106
• TABLE 4.5 LEADING INJECTABLE DRUG DELIVERY COMPANIES 2007, KEY PRODUCTS AND SALES 2007 ($ MN)109
• TABLE 4.6 KEY TRANSMUCOSAL DRUG DELIVERY PRODUCTS, 2004-2007**118
• ($ MN)118
• TABLE 4.7 KEY TRANSDERMAL DRUG DELIVERY PRODUCTS, 2004-2007#128
• ($ MN)128
• TABLE 4.8 KEY TOPICAL DRUG DELIVERY PRODUCTS, 2007138
• TABLE 4.9 KEY NICHE DRUG DELIVERY PRODUCTS, 2004-2007 ($ MN)140
• TABLE 5.1 KEY ORAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008144
• TABLE 6.1 KEY INHALABLE DRUG DELIVERY R&D PIPELINE DRUGS, 2008167
• TABLE 7.1 KEY INJECTABLE DRUG DELIVERY R&D PIPELINE DRUGS, 2008176
• TABLE 8.1 KEY TRANSMUCOSAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008188
• TABLE 9.1 KEY TRANSDERMAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008197
• TABLE 10.1 KEY TOPICAL DRUG DELIVERY R&D PIPELINE DRUGS, 2008209
• TABLE 10.2 KEY NICHE DRUG DELIVERY R&D PIPELINE DRUGS, 2008210
• TABLE 11.1 3M KEY FINANCIALS, 2003-2007 (US$MN)224
• TABLE 11.2 3M DRUG DELIVERY PORTFOLIO, 2008225
• TABLE 11.3 ALKERMES KEY FINANCIALS, 2003-2007 (US$MN)226
• TABLE 11.4 ALKERMES DRUG DELIVERY PORTFOLIO, 2008227
• TABLE 11.5 ALTEA THERAPEUTICS DRUG DELIVERY PORTFOLIO, 2008228
• TABLE 11.6 ALZA DRUG DELIVERY PORTFOLIO, 2008229
• TABLE 11.7 ARADIGM KEY FINANCIALS, 2003-2007 (US$MN)231
• TABLE 11.8 ARADIGM DRUG DELIVERY PORTFOLIO, 2008232
• TABLE 11.9 BIOJECT KEY FINANCIALS, 2003-2007 (US$MN)233
• TABLE 11.10 BIOJECT DRUG DELIVERY PORTFOLIO, 2008233
• TABLE 11.11 BIOVAIL KEY FINANCIALS, 2003-2007 (US$MN)234
• TABLE 11.12 BIOVAIL DRUG DELIVERY PORTFOLIO, 2008235
• TABLE 11.13 CARDINAL HEALTH KEY FINANCIALS, 2003-2007 (US$MN)236
• TABLE 11.14 CARDINAL HEALTH DRUG DELIVERY PORTFOLIO, 2008237
• TABLE 11.15 CEPHALON KEY FINANCIALS, 2003-2007 (US$MN)238
• TABLE 11.16 CIMA LABS DRUG DELIVERY PORTFOLIO, 2008238
• TABLE 11.17 CONNETICS KEY FINANCIALS, 2003-2007 (US$MN)240
• TABLE 11.18 CONNETICS DRUG DELIVERY PORTFOLIO, 2008240
• TABLE 11.19 CYDEX DRUG DELIVERY PIPELINE, 2008242
• TABLE 11.20 CARRINGTON LABORATORIES KEY FINANCIALS, 2003-2007 (US$MN)243
• TABLE 11.21 DEPOMED KEY FINANCIALS, 2003-2007 (US$MN)244
• TABLE 11.22 DEPOMED DRUG DELIVERY PORTFOLIO, 2008245
• TABLE 11.23 DOR BIOPHARMA KEY FINANCIALS, 2003-2007 (US$MN)246
• TABLE 11.24 DOR BIOPHARMA DRUG DELIVERY PORTFOLIO, 2008246
• TABLE 11.25 DURECT KEY FINANCIALS, 2003-2007 (US$MN)247
• TABLE 11.26 DURECT DRUG DELIVERY PORTFOLIO, 2008248
• TABLE 11.27 EMISPHERE KEY FINANCIALS, 2003-2007 (US$MN)249
• TABLE 11.28 EMISPHERE DRUG DELIVERY PORTFOLIO, 2008250
• TABLE 11.29 ENZON KEY FINANCIALS, 2003-2007 (US$MN)251
• TABLE 11.30 ENZON DRUG DELIVERY PORTFOLIO, 2008252
• TABLE 11.31 ETHYPHARM DRUG DELIVERY PORTFOLIO, 2008253
• TABLE 11.32 EURAND KEY FINANCIALS, 2003-2007 (US$MN)255
• TABLE 11.33 EURAND DRUG DELIVERY PORTFOLIO, 2008256
• TABLE 11.34 GENEREX KEY FINANCIALS, 2003-2007 (US$MN)257
• TABLE 11.35 GENEREX DRUG DELIVERY PORTFOLIO, 2008257
• TABLE 11.36 INOVIO KEY FINANCIALS, 2003-2007 (US$MN)258
• TABLE 11.37 INOVIO DRUG DELIVERY PORTFOLIO, 2008259
• TABLE 11.38 IVAX KEY FINANCIALS, 2003-2007 (US$MN)261
• TABLE 11.39 IVAX DRUG DELIVERY PORTFOLIO, 2008262
• TABLE 11.40 MACROCHEM KEY FINANCIALS, 2003-2007 (US$MN)263
• TABLE 11.41 MACROCHEM DRUG DELIVERY PORTFOLIO, 2008263
• TABLE 11.42 MACROMED DRUG DELIVERY PORTFOLIO, 2008264
• TABLE 11.43 NASTECH KEY FINANCIALS, 2003-2007 (US$MN)265
• TABLE 11.44 NASTECH DRUG DELIVERY PORTFOLIO, 2008266
• TABLE 11.45 NEKTAR KEY FINANCIALS, 2003-2007 (US$MN)267
• TABLE 11.46 NEKTAR DRUG DELIVERY PORTFOLIO, 2008267
• TABLE 11.47 NEXMED KEY FINANCIALS, 2003-2007 (US$MN)269
• TABLE 11.48 NEXMED DRUG DELIVERY PORTFOLIO, 2008270
• TABLE 11.49 NOVEN KEY FINANCIALS, 2003-2007 (US$MN)271
• TABLE 11.50 NOVEN DRUG DELIVERY PORTFOLIO, 2008271
• TABLE 11.51 PSIVIDA KEY FINANCIALS, 2003-2007 (US$MN)273
• TABLE 11.52 PSIVIDA DRUG DELIVERY PORTFOLIO, 2008273
• TABLE 11.53 PENWEST KEY FINANCIALS, 2003-2007 (US$MN)274
• TABLE 11.54 PENWEST DRUG DELIVERY PORTFOLIO, 2008275
• TABLE 11.55 PHERIN PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008276
• TABLE 11.56 QLT KEY FINANCIALS, 2003-2007 (US$MN)277
• TABLE 11.57 QLT DRUG DELIVERY PORTFOLIO, 2008278
• TABLE 11.58 SKYE PHARMA KEY FINANCIALS, 2003-2007 (US$MN)279
• TABLE 11.59 SKYEPHARMA DRUG DELIVERY PORTFOLIO, 2008280
• TABLE 11.60 WATSON KEY FINANCIALS, 2003-2007 (US$MN)281
• TABLE 11.61 WATSON PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008282
• TABLE 11.62 ZOGENIX PHARMACEUTICALS DRUG DELIVERY PORTFOLIO, 2008283
• Graphs
• GRAPH 3.1 ESTIMATED DRUG DELIVERY MARKET BY MAIN GEOGRAPHIC REGIONS71
• GRAPH 3.2 GLOBAL SALES OF DRUG DELIVERY SYSTEMS BY KEY SEGMENTS, 200773
• GRAPH 3.3 FORECAST GLOBAL SALES OF DRUG DELIVERY MARKET BY SEGMENT, US$ BILLION75
• GRAPH 3.4 FORECAST 2007-2012 GROWTH OF GLOBAL DRUG DELIVERY MARKET BY SEGMENT76
• GRAPH 4.1 TOP 5 PRODUCTS UTILIZING ORAL DELIVERY, GLOBAL SALES 2007 ($ MN)82
• GRAPH 4.2 LEADING ORAL DRUG DELIVERY COMPANIES, COMBINED KEY PRODUCT VALUES 2007 ($ MN)84
• GRAPH 4.3 KEY THERAPEUTIC AREAS OF EMPHASIS FOR ORAL DRUG DELIVERY, # OF KEY MARKETED PRODUCTS, 200785
• GRAPH 4.4 TOP 5 PRODUCTS UTILIZING INHALABLE DELIVERY, GLOBAL SALES 2007 ($ MN)96
• GRAPH 4.5 INHALABLE DRUG DELIVERY MARKET SHARE, BY TECHNOLOGY 200796
• GRAPH 4.6 TOP 5 PRODUCTS UTILIZING INJECTABLE DELIVERY, GLOBAL SALES 2007 ($ MN)108
• GRAPH 4.7 LEADING INJECTABLE DRUG DELIVERY COMPANIES, COMBINED KEY PRODUCT VALUES 2007 ($ MN)110
• GRAPH 4.8 TOP 5 PRODUCTS UTILIZING TRANSMUCOSAL DELIVERY, GLOBAL SALES 2007 ($ MN)119
• GRAPH 4.9 LEADING DEVELOPERS OF TRANSMUCOSAL-BASED THERAPEUTICS 2007 ($ MN)120
• GRAPH 4.10 LEADING TRANSDERMAL DRUG DELIVERY COMPANIES, BY # OF PRODUCTS ON MARKET130
• GRAPH 4.11 KEY THERAPEUTIC AREAS OF EMPHASIS FOR TRANSDERMAL DRUG DELIVERY, # OF KEY MARKETED PRODUCTS131
• GRAPH 5.1 LEADING COMPANIES ACTIVE IN ORAL DRUG DELIVERY DEVELOPMENT150
• GRAPH 5.2 LEADING INDICATIONS FOR ORAL DRUG DELIVERY PRODUCTS IN DEVELOPMENT151
• GRAPH 6.1 LEADING COMPANIES ACTIVE IN INHALABLE DRUG DELIVERY DEVELOPMENT168
• GRAPH 7.1 LEADING COMPANIES ACTIVE IN INJECTABLE DRUG DELIVERY DEVELOPMENT179
• GRAPH 8.1 LEADING COMPANIES ACTIVE IN INJECTABLE DRUG DELIVERY DEVELOPMENT189
• GRAPH 9.1 LEADING COMPANIES ACTIVE IN TRANSDERMAL DRUG DELIVERY DEVELOPMENT198
• GRAPH 10.1 LEADING COMPANIES ACTIVE IN NICHE/TOPICAL DRUG DELIVERY DEVELOPMENT211
• Figures
• FIGURE 1.1 OPTIMAL TIME FOR REFORMULATION19
• FIGURE 1.2 GROWTH PROSPECTS IN THE DRUG DELIVERY SECTOR21
• FIGURE 2.1 PULSATILE DRUG RELEASE34
•  

Other users found this report page using the following search terms: drug delivery drug delivery market transdermal future pulsatile oral technologies global topical

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.